Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
Advertisement Article continues below this ad Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different ...
NetraMark Holdings ( ($TSE:AIAI) ) just unveiled an update. NetraMark has announced the launch of NetraAI 2.0, an advanced platform aimed at ...
SCOPE Conference (Summit for Clinical Ops Executives), held last week in Orlando, FL, brought together more than 4,500 industry ...
In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
Turmeric and honey contain beneficial compounds that can help reduce inflammation, improve metabolic health, and aid in ...
A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...
About Image Analysis Group (IAG ... reliably supporting all aspects of phase I to IV imaging trials across multiple indications. With a pioneering, proven innovation strategy, we enhance novel ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback